AnalystRatingsNetwork.com reports. The analysts wrote, “Summary...

AnalystRatingsNetwork.com reports.

The analysts wrote, “Summary We spoke with Benitec management and left our call disappointed with news that the HCV (one shot, one cure) program is being dropped. Management mentioned changes in the competitive landscape as the reason. We are a bit baffled by this as we have known for some time that Harvoni has changed the way HCV is treated. Has the competitive landscape changed that munch since the summer IPO? The loss of Peter French as the CEO, coupled with a lack of progress and now suspension of the HCV program forces our hand at what we now consider to be a distressed valuation. We acknowledge Benitec has a recovery window but it is narrowing, in our view.””